Morten Scheibye-Knudsen
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Morten Scheibye-Knudsen.
Nature Communications | 2013
Alejandro Martin-Montalvo; Evi M. Mercken; Sarah J. Mitchell; Hector H. Palacios; Patricia L. Mote; Morten Scheibye-Knudsen; Ana P. Gomes; Theresa M. Ward; Robin K. Minor; Marie-José Blouin; Matthias Schwab; Michael Pollak; Yongqing Zhang; Yinbing Yu; Kevin G. Becker; Vilhelm A. Bohr; Donald K. Ingram; David A. Sinclair; Norman S. Wolf; Stephen R. Spindler; Michel Bernier; Rafael de Cabo
Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced LDL and cholesterol levels without a decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein kinase activity and increases antioxidant protection, resulting in reductions in both oxidative damage accumulation and chronic inflammation. Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in agreement with current epidemiological data and raise the possibility of metformin-based interventions to promote healthy aging.
Cell | 2014
Evandro Fei Fang; Morten Scheibye-Knudsen; Lear E. Brace; Henok Kassahun; Tanima SenGupta; Hilde Nilsen; James R. Mitchell; Deborah L. Croteau; Vilhelm A. Bohr
Mitochondrial dysfunction is a common feature in neurodegeneration and aging. We identify mitochondrial dysfunction in xeroderma pigmentosum group A (XPA), a nucleotide excision DNA repair disorder with severe neurodegeneration, in silico and in vivo. XPA-deficient cells show defective mitophagy with excessive cleavage of PINK1 and increased mitochondrial membrane potential. The mitochondrial abnormalities appear to be caused by decreased activation of the NAD(+)-SIRT1-PGC-1α axis triggered by hyperactivation of the DNA damage sensor PARP-1. This phenotype is rescued by PARP-1 inhibition or by supplementation with NAD(+) precursors that also rescue the lifespan defect in xpa-1 nematodes. Importantly, this pathogenesis appears common to ataxia-telangiectasia and Cockayne syndrome, two other DNA repair disorders with neurodegeneration, but absent in XPC, a DNA repair disorder without neurodegeneration. Our findings reveal a nuclear-mitochondrial crosstalk that is critical for the maintenance of mitochondrial health.
Scientific Reports | 2011
Robin K. Minor; Joseph A. Baur; Ana P. Gomes; Theresa M. Ward; Anna Csiszar; Evi M. Mercken; Kotb Abdelmohsen; Yu Kyong Shin; Carles Cantó; Morten Scheibye-Knudsen; Melissa Krawczyk; Pablo M. Irusta; Alejandro Martin-Montalvo; Basil P. Hubbard; Yongqing Zhang; Elin Lehrmann; Alexa A. White; Nathan L. Price; William R. Swindell; Kevin J. Pearson; Kevin G. Becker; Vilhelm A. Bohr; Myriam Gorospe; Josephine M. Egan; Mark I. Talan; Johan Auwerx; Christoph H. Westphal; James L. Ellis; Zoltan Ungvari; George P. Vlasuk
Sirt1 is an NAD+-dependent deacetylase that extends lifespan in lower organisms and improves metabolism and delays the onset of age-related diseases in mammals. Here we show that SRT1720, a synthetic compound that was identified for its ability to activate Sirt1 in vitro, extends both mean and maximum lifespan of adult mice fed a high-fat diet. This lifespan extension is accompanied by health benefits including reduced liver steatosis, increased insulin sensitivity, enhanced locomotor activity and normalization of gene expression profiles and markers of inflammation and apoptosis, all in the absence of any observable toxicity. Using a conditional SIRT1 knockout mouse and specific gene knockdowns we show SRT1720 affects mitochondrial respiration in a Sirt1- and PGC-1α-dependent manner. These findings indicate that SRT1720 has long-term benefits and demonstrate for the first time the feasibility of designing novel molecules that are safe and effective in promoting longevity and preventing multiple age-related diseases in mammals.
Cell Metabolism | 2014
Morten Scheibye-Knudsen; Sarah J. Mitchell; Evandro Fei Fang; Teruaki Iyama; Theresa M. Ward; James Wang; Christopher Dunn; Nagendra S. Singh; Sebastian Veith; Mahdi Hasan-Olive; Aswin Mangerich; Mark A. Wilson; Mark P. Mattson; Linda H. Bergersen; Victoria C. Cogger; Alessandra Warren; David G. Le Couteur; Ruin Moaddel; David M. Wilson; Deborah L. Croteau; Rafael de Cabo; Vilhelm A. Bohr
Cockayne syndrome (CS) is an accelerated aging disorder characterized by progressive neurodegeneration caused by mutations in genes encoding the DNA repair proteins CS group A or B (CSA or CSB). Since dietary interventions can alter neurodegenerative processes, Csb(m/m) mice were given a high-fat, caloric-restricted, or resveratrol-supplemented diet. High-fat feeding rescued the metabolic, transcriptomic, and behavioral phenotypes of Csb(m/m) mice. Furthermore, premature aging in CS mice, nematodes, and human cells results from aberrant PARP activation due to deficient DNA repair leading to decreased SIRT1 activity and mitochondrial dysfunction. Notably, β-hydroxybutyrate levels are increased by the high-fat diet, and β-hydroxybutyrate, PARP inhibition, or NAD(+) supplementation can activate SIRT1 and rescue CS-associated phenotypes. Mechanistically, CSB can displace activated PARP1 from damaged DNA to limit its activity. This study connects two emerging longevity metabolites, β-hydroxybutyrate and NAD(+), through the deacetylase SIRT1 and suggests possible interventions for CS.
Trends in Cell Biology | 2015
Morten Scheibye-Knudsen; Evandro Fei Fang; Deborah L. Croteau; David M. Wilson; Vilhelm A. Bohr
Mitochondria are the oxygen-consuming power plants of cells. They provide a critical milieu for the synthesis of many essential molecules and allow for highly efficient energy production through oxidative phosphorylation. The use of oxygen is, however, a double-edged sword that on the one hand supplies ATP for cellular survival, and on the other leads to the formation of damaging reactive oxygen species (ROS). Different quality control pathways maintain mitochondria function including mitochondrial DNA (mtDNA) replication and repair, fusion-fission dynamics, free radical scavenging, and mitophagy. Further, failure of these pathways may lead to human disease. We review these pathways and propose a strategy towards a treatment for these often untreatable disorders.
The FASEB Journal | 2010
Maria D. Aamann; Martin M. Sørensen; Christina Hvitby; Brian R. Berquist; Meltem Muftuoglu; Jingyan Tian; Nadja C. de Souza-Pinto; Morten Scheibye-Knudsen; David M. Wilson; Tinna Stevnsner; Vilhelm A. Bohr
Cockayne syndrome (CS) is a human premature aging disorder associated with severe developmental deficiencies and neurodegeneration, and phenotypically it resembles some mitochondrial DNA (mtDNA) diseases. Most patients belong to complementation group B, and the CS group B (CSB) protein plays a role in genomic maintenance and transcriptome regulation. By immunocytochemistry, mitochondrial fractionation, and Western blotting, we demonstrate that CSB localizes to mitochondria in different types of cells, with increased mitochondrial distribution following menadione‐induced oxidative stress. Moreover, our results suggest that CSB plays a significant role in mitochondrial base excision repair (BER) regulation. In particular, we find reduced 8‐oxo‐guanine, uracil, and 5‐hydroxy‐uracil BER incision activities in CSBdeficient cells compared to wild‐type cells. This deficiency correlates with deficient association of the BER activities with the mitochondrial inner membrane, suggesting that CSB may participate in the anchoring of the DNA repair complex. Increased mutation frequency in mtDNA of CSB‐deficient cells demonstrates functional significance of the presence of CSB in the mitochondria. The results in total suggest that CSB plays a direct role in mitochondrial BER by helping recruit, stabilize, and/or retain BER proteins in repair complexes associated with the inner mitochondrial membrane, perhaps providing a novel basis for understanding the complex phenotype of this debilitating disorder.—Aamann, M. D., Sorensen, M. M., Hvitby, C, Berquist, B. R, Muftuoglu, M., Tian, J., de Souza‐Pinto, N. C, Scheibye‐Knudsen, M., Wilson, D. M., III, Stevnsner, T., Bohr, V. A Cockayne syndrome group B protein promotes mitochondrial DNA stability by supporting the DNA repair association with the mitochondrial membrane. FASEBJ. 24, 2334–2346 (2010). www.fasebj.org
Aging Cell | 2014
Evi M. Mercken; Sarah J. Mitchell; Alejandro Martin-Montalvo; Robin K. Minor; Maria Almeida; Ana P. Gomes; Morten Scheibye-Knudsen; Hector H. Palacios; Jordan J Licata; Yongqing Zhang; Kevin G. Becker; Husam Khraiwesh; José A. González-Reyes; José M. Villalba; Joseph A. Baur; Peter J. Elliott; Christoph H. Westphal; George P. Vlasuk; James L. Ellis; David A. Sinclair; Michel Bernier; Rafael de Cabo
Increased expression of SIRT1 extends the lifespan of lower organisms and delays the onset of age‐related diseases in mammals. Here, we show that SRT2104, a synthetic small molecule activator of SIRT1, extends both mean and maximal lifespan of mice fed a standard diet. This is accompanied by improvements in health, including enhanced motor coordination, performance, bone mineral density, and insulin sensitivity associated with higher mitochondrial content and decreased inflammation. Short‐term SRT2104 treatment preserves bone and muscle mass in an experimental model of atrophy. These results demonstrate it is possible to design a small molecule that can slow aging and delay multiple age‐related diseases in mammals, supporting the therapeutic potential of SIRT1 activators in humans.
Journal of Biological Chemistry | 2011
Michel Bernier; Rajib K. Paul; Alejandro Martin-Montalvo; Morten Scheibye-Knudsen; Shaoming Song; Hua-Jun He; Sean M. Armour; Basil P. Hubbard; Vilhelm A. Bohr; Lili Wang; Yaping Zong; David A. Sinclair; Rafael de Cabo
In mammals, the transcriptional activity of signal transducer and activator of transcription 3 (STAT3) is regulated by the deacetylase SIRT1. However, whether the newly described nongenomic actions of STAT3 toward mitochondrial oxidative phosphorylation are dependent on SIRT1 is unclear. In this study, Sirt1 gene knock-out murine embryonic fibroblast (MEF) cells were used to delineate the role of SIRT1 in the regulation of STAT3 mitochondrial function. Here, we show that STAT3 mRNA and protein levels and the accumulation of serine-phosphorylated STAT3 in mitochondria were increased significantly in Sirt1-KO cells as compared with wild-type MEFs. Various mitochondrial bioenergetic parameters, such as the oxygen consumption rate in cell cultures, enzyme activities of the electron transport chain complexes in isolated mitochondria, and production of ATP and lactate, indicated that Sirt1-KO cells exhibited higher mitochondrial respiration as compared with wild-type MEFs. Two independent approaches, including ectopic expression of SIRT1 and siRNA-mediated knockdown of STAT3, led to reduction in intracellular ATP levels and increased lactate production in Sirt1-KO cells that were approaching those of wild-type controls. Comparison of profiles of phospho-antibody array data indicated that the deletion of SirT1 was accompanied by constitutive activation of the pro-inflammatory NF-κB pathway, which is key for STAT3 induction and increased cellular respiration in Sirt1-KO cells. Thus, SIRT1 appears to be a functional regulator of NF-κB-dependent STAT3 expression that induces mitochondrial biogenesis. These results have implications for understanding the interplay between STAT3 and SIRT1 in pro-inflammatory conditions.
Cell Metabolism | 2016
Sarah J. Mitchell; Morten Scheibye-Knudsen; Evandro Fei Fang; Miguel A. Aon; José A. González-Reyes; Sonia Cortassa; Susmita Kaushik; Marta Gonzalez-Freire; Bindi Patel; Devin Wahl; Ahmed Ali; Miguel Calvo-Rubio; María I. Burón; Vincent Guiterrez; Theresa M. Ward; Hector H. Palacios; Huan Cai; David W. Frederick; Christopher Hine; Filomena Broeskamp; Lukas Habering; John A Dawson; T. Mark Beasley; Junxiang Wan; Yuji Ikeno; Gene Hubbard; Kevin G. Becker; Yongqing Zhang; Vilhelm A. Bohr; Dan L. Longo
Calorie restriction (CR) is the most robust non-genetic intervention to delay aging. However, there are a number of emerging experimental variables that alter CR responses. We investigated the role of sex, strain, and level of CR on health and survival in mice. CR did not always correlate with lifespan extension, although it consistently improved health across strains and sexes. Transcriptional and metabolomics changes driven by CR in liver indicated anaplerotic filling of the Krebs cycle together with fatty acid fueling of mitochondria. CR prevented age-associated decline in the liver proteostasis network while increasing mitochondrial number, preserving mitochondrial ultrastructure and function with age. Abrogation of mitochondrial function negated life-prolonging effects of CR in yeast and worms. Our data illustrate the complexity of CR in the context of aging, with a clear separation of outcomes related to health and survival, highlighting complexities of translation of CR into human interventions.
Nature Reviews Molecular Cell Biology | 2016
Evandro Fei Fang; Morten Scheibye-Knudsen; Katrin F. Chua; Mark P. Mattson; Deborah L. Croteau; Vilhelm A. Bohr
Mitochondrial dysfunction is a hallmark of ageing, and mitochondrial maintenance may lead to increased healthspan. Emerging evidence suggests a crucial role for signalling from the nucleus to mitochondria (NM signalling) in regulating mitochondrial function and ageing. An important initiator of NM signalling is nuclear DNA damage, which accumulates with age and may contribute to the development of age-associated diseases. DNA damage-dependent NM signalling constitutes a network that includes nuclear sirtuins and controls genomic stability and mitochondrial integrity. Pharmacological modulation of NM signalling is a promising novel approach for the prevention and treatment of age-associated diseases.